Acute toxicity of second generation HIV protease-inhibitors in combination with radiotherapy: A retrospective case series

Radiation Oncology

Volumn 6, Issue 1, 2011, Pages

  See, Alfred P ^a   Zeng, Jing ^b   Tran, Phuoc T ^b   Lim, Michael ^a,b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EFAVIRENZ; EMTRICITABINE; FLUOROURACIL; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; MITOMYCIN C; PREDNISONE; RALTEGRAVIR; SUNITINIB; TENOFOVIR; VINCRISTINE; ZIDOVUDINE;

ANDROGEN DEPRIVATION THERAPY; ANOREXIA; ANUS CANCER; ARTICLE; BILE DUCT CARCINOMA; CANCER RADIOTHERAPY; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DYSURIA; FATIGUE; FRACTIONATION; GROUPS BY AGE; HEMATOCHEZIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPIGMENTATION; KIDNEY CARCINOMA; MEDICAL RECORD REVIEW; NECK CANCER; NOCTURIA; NONHODGKIN LYMPHOMA; PAIN; PROCTITIS; PRURITUS; RADIATION DOSE; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; URINARY FREQUENCY; URINE INCONTINENCE; UTERINE CERVIX CANCER; ACUTE DISEASE; ADULT; AGED; DRUG TOXICITY; EVALUATION; FOLLOW UP; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RETROSPECTIVE STUDY;

ACUTE DISEASE; ADULT; AGED; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; DRUG TOXICITY; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MIDDLE AGED; NEOPLASMS; RADIATION INJURIES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79952694277     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-6-25     Document Type: Article

References (55)

1. Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D, . Clin Epidemiology Grp F-AC Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncology 2009, 10(12):1152-1159. 10.1016/S1470-2045(09)70282-7, 19818686, Clin Epidemiology Grp F-AC.
2. Shiels MS, Pfeiffer RM, Engels EA. Age at Cancer Diagnosis Among Persons With AIDS in the United States. Annals of Internal Medicine 2010, 153(7):452-+.
3. Simard EP, Engels EA. Cancer as a Cause of Death among People with AIDS in the United States. Clinical Infectious Diseases 2010, 51(8):957-962. 10.1086/656416, 20825305.
4. Grogg KL, Miller RF, Dogan A. HIV infection and lymphoma. Journal of Clinical Pathology 2007, 60(12):1365-1372. 10.1136/jcp.2007.051953, 2095580, 18042692.
5. Silverberg MJ, Abrams DI. AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Current Opinion in Oncology 2007, 19(5):446-451.
6. Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, Wood E, Montaner JSG. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. Aids 2007, 21:685-692. 10.1097/QAD.0b013e32802ef30c, 17413689.
7. Crum NF, Riffenburgh RH, Wegner S, Agan BK, Tasker SA, Spooner KM, Armstrong AW, Fraser S, Wallace MR, Triservice ACC. Comparisons of causes of death and mortality rates among HIV-infected persons - Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. Jaids-Journal of Acquired Immune Deficiency Syndromes 2006, 41(2):194-200.
8. Lewden C, Salmon D, Morlat P, Bevilacqua S, Jougla E, Bonnet F, Heripret L, Costagliola D, May T, Chene G. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. International Journal of Epidemiology 2005, 34(1):121-130. 10.1093/ije/dyh307, 15561752.
9. Burgi A, Brodine S, Wegner S, Milazzo M, Wallace MR, Spooner K, Blazes DL, Agan BK, Armstrong A, Fraser S, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005, 104(7):1505-1511. 10.1002/cncr.21334, 16104038.
10. Housri N, Yarchoan R, Kaushal A. Radiotherapy for Patients With the Human Immunodeficiency Virus: Are Special Precautions Necessary?. Cancer 2010, 116(2):273-283. 10.1002/cncr.24878, 20014399.
11. Plastaras JP, Vapiwala N, Ahmed MS, Gudonis D, Cerniglia GJ, Feldman MD, Frank I, Gupta AK. Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans. Cancer Biology & Therapy 2008, 7(5):628-635.
12. Vallis KA. Glutathione deficiency and radiosensitivity in AIDS patients. Lancet 1991, 337(8746):918-919. 10.1016/0140-6736(91)90250-S, 1672996.
13. Baeyens A, Slabbert JP, Willem P, Jozela S, Van Der Merwe D, Vral A. Chromosomal radiosensitivity of HIV positive individuals. International Journal of Radiation Biology 2010, 86(7):584-592. 10.3109/09553001003734576, 20545573.
14. Sun Y, Huang YC, Xu QZ, Wang HP, Bai B, Sul JL, Zhou PK. HIV-1 Tat depresses DNA-PKCS expression and DNA repair, and sensitizes cells to ionizing radiation. International Journal of Radiation Oncology Biology Physics 2006, 65(3):842-850.
15. Chaurushiya MS, Weitzman MD. Viral manipulation of DNA repair and cell cycle checkpoints. DNA Repair 2009, 8(9):1166-1176. 10.1016/j.dnarep.2009.04.016, 2725192, 19473887.
16. Klas JV, Rothenberger DA, Wong WD, Madoff RD. Malignant tumors of the anal canal - The spectrum of disease, treatment, and outcomes. Cancer 1999, 85(8):1686-1693. 10.1002/(SICI)1097-0142(19990415)85:8<1686::AID-CNCR7>3.0.CO;2-7, 10223561.
17. Eastham JA, Evans CP, Zietman A. What is the optimal management of high risk, clinically localized prostate cancer?. Urologic Oncology-Seminars and Original Investigations 2010, 28(5):557-567.
18. Du XL, Freeman JL, Nattinger AB, Goodwin JS. Survival of women after breast conserving surgery for early stage breast cancer. Breast Cancer Research and Treatment 2002, 72(1):23-31. 10.1023/A:1014908802632, 12000218.
19. Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, Nomura Y, Sakai K, Sugimachi K, Tominaga T, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 366(9503):2087-2106.
20. Srokowski TR, Fang SY, Duan ZG, Buchholz TA, Hortobagyi GN, Goodwin JS, Giordano SH. Completion of adjuvant radiation therapy among women with breast cancer. Cancer 2008, 113(1):22-29. 10.1002/cncr.23513, 18442124.
21. Stier E. Cervical neoplasia and the HIV-infected patient. Hematology-Oncology Clinics of North America 2003, 17(3):873-+.
22. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors - A review for clinicians. Jama-Journal of the American Medical Association 1997, 277(2):145-153.
23. Behrens GMN, Boerner AR, Weber K, van den Hoff J, Ockenga J, Brabant G, Schmidt RE. Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. Journal of Clinical Investigation 2002, 110(9):1319-1327. 151608, 12417571.
24. Aboud M, Elgalib A, Kulasegaram R, Peters B. Insulin resistance and HIV infection: a review. International Journal of Clinical Practice 2007, 61(3):463-472. 10.1111/j.1742-1241.2006.01267.x, 17313615.
25. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998, 351(9119):1881-1883. 10.1016/S0140-6736(98)03391-1, 9652687.
26. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. Journal of Biological Chemistry 2000, 275(27):20251-20254. 10.1074/jbc.C000228200, 10806189.
27. Gupta AK, Cerniglia GJ, Mick R, McKenna WG, Muschel RJ. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Research 2005, 65(18):8256-8265. 10.1158/0008-5472.CAN-05-1220, 16166302.
28. Yang Y, Ikezoe T, Nishioka C, Bandobashi K, Takeuchi T, Adachi Y, Kobayashi M, Takeuchi S, Koeffler HP, Taguchi H. NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines. British Journal of Cancer 2006, 95(12):1653-1662. 10.1038/sj.bjc.6603435, 2360758, 17133272.
29. Bernstein WB, Dennis PA. Repositioning HIV protease inhibitors as cancer therapeutics. Curr Opin HIV AIDS 2008, 3(6):666-675. 10.1097/COH.0b013e328313915d, 2682221, 19373040.
30. Ikezoe T, Saito T, Bandobashi K, Yang Y, Koeffler HP, Taguchi H. HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2. Molecular Cancer Therapeutics 2004, 3(4):473-479.
31. Jiang W, Mikochik PJ, Ra JH, Lei HQ, Flaherty KT, Winkler JD, Spitz FR. HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. Cancer Research 2007, 67(3):1221-1227. 10.1158/0008-5472.CAN-06-3377, 17283158.
32. Srirangam A, Mitra R, Wang M, Gorski JC, Badve S, Baldridge L, Hamilton J, Kishimoto H, Hawes J, Li L, et al. Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clinical Cancer Research 2006, 12(6):1883-1896. 10.1158/1078-0432.CCR-05-1167, 2727652, 16551874.
33. Yang Y, Ikezoe T, Takeuchi T, Adachi Y, Ohtsuki Y, Takeuchi S, Koeffler HP, Taguchi H. HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling. Cancer Science 2005, 96(7):425-433. 10.1111/j.1349-7006.2005.00063.x, 16053514.
34. Pyrko P, Kardosh A, Wang W, Xiong W, Schonthal AH, Chen TC. HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Research 2007, 67(22):10920-10928. 10.1158/0008-5472.CAN-07-0796, 18006837.
35. Gills J, Lo Piccolo J, Tsurutani J, Shoemaker RH, Best CJM, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, et al. Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clinical Cancer Research 2007, 13(17):5183-5194. 10.1158/1078-0432.CCR-07-0161, 17785575.
36. Pajonk F, Himmelsbach J, Riess K, Sommer A, McBride WH. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Research 2002, 62(18):5230-5235.
37. Crum-Cianflone NE, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, Fraser S, Roediger MP, Agan B, Regner S. The Impact of Nelfinavir Exposure on Cancer Development Among a Large Cohort of HIV-Infected Patients. Jaids-Journal of Acquired Immune Deficiency Syndromes 2009, 51(3):305-309.
38. Maggiorella L, Wen BX, Frascogna V, Opolon P, Bourhis J, Deutsch E. Combined radiation sensitizing and anti-angiogenic effects of ionizing radiation and the protease inhibitor Ritonavir in a head and neck carcinoma model. Anticancer Research 2005, 25(6B):4357-4362.
39. Pore N, Gupta AK, Cerniglia GJ, Jiang ZB, Bernhard EJ, Evans SM, Koch CJ, Hahn SM, Maity A. Nelfinavir down-regulates hypoxia-inducible factor 1 alpha and VEGF expression and increases tumor oxygenation: Implications for radiotherapy. Cancer Research 2006, 66(18):9252-9259. 10.1158/0008-5472.CAN-06-1239, 16982770.
40. Bachtiary B, Schindl M, Potter R, Dreier B, Knocke TH, Hainfellner JA, Horvat R, Birner P. Overexpression of hypoxia-inducible factor 1 alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clinical Cancer Research 2003, 9(6):2234-2240.
41. Arvold ND, Guha N, Wang DF, Matli M, Deen DF, Warren RS, Haas-Kogan DA. Hypoxia-induced radioresistance is independent of hypoxia-inducible factor-1A in vitro. International Journal of Radiation Oncology Biology Physics 2005, 62(1):207-212.
42. Zou YF, Cheng C, Omura-Minamisawa M, Kang Y, Hara T, Guan XH, Inoue T. The Suppression of Hypoxia-inducible Factor and Vascular Endothelial Growth Factor by siRNA Does not Affect the Radiation Sensitivity of Multicellular Tumor Spheroids. Journal of Radiation Research 2010, 51(1):47-55. 10.1269/jrr.09070, 19959878.
43. Kim IA, Fernandes AT, Gupta AK, McKenna WG, Bernhard EJ. The influence of Ras pathway signaling on tumor radiosensitivity. Cancer and Metastasis Reviews 2004, 23(3-4):227-236. 10.1023/B:CANC.0000031763.95152.09, 15197325.
44. Kim IA, Bae SS, Fernandes A, Wu JM, Muschel RJ, McKenna WG, Birnbaum MJ, Bernhard EJ. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Research 2005, 65(17):7902-7910.
45. Kimple RJ, Vaseva AV, Cox AD, Baerman KM, Calvo BF, Tepper JE, Shields JM, Sartor CI. Radiosensitization of Epidermal Growth Factor Receptor/HER2-Positive Pancreatic Cancer Is Mediated by Inhibition of Akt Independent of Ras Mutational Status. Clinical Cancer Research 2010, 16(3):912-923. 10.1158/1078-0432.CCR-09-1324, 2818631, 20103665.
46. Gupta AK, Lee JH, Wilke WW, Quon H, Smith G, Maity A, Buatti JM, Spitz DR. Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-hpv-infected cell line and relationship to signaling through AKT. International Journal of Radiation Oncology Biology Physics 2009, 74(3):928-933.
47. Chai H, Yang H, Yan SY, Li M, Lin PH, Lumsden AB, Yao Q, Chen CY. Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries. Jaids-Journal of Acquired Immune Deficiency Syndromes 2005, 40(1):12-19.
48. Cuneo KC, Tu TX, Geng L, Fu AL, Hallahan DE, Willey CD. HIV protease inhibitors enhance the efficacy of irradiation. Cancer Research 2007, 67(10):4886-4893. 10.1158/0008-5472.CAN-06-3684, 17510418.
49. Edwards E, Geng L, Tan J, Onishko H, Donnelly E, Hallahan DE. Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Research 2002, 62(16):4671-4677.
50. Chapman CH, Shen J, Filion EJ, Tran PT, Hara W, Asuncion A, Marko D, Wakelee H, Berry GJ, Dimmick KW, et al. Marked Tumor Response and Fatal Hemoptysis During Radiation for Lung Cancer in a Human Immunodeficiency Virus-Positive Patient Taking Nelfinavir. Journal of Thoracic Oncology 2009, 4(12):1587-1589. 10.1097/JTO.0b013e3181bf111d, 20009915.
51. Hocht S, Wiegel T, Kroesen AJ, Berdel WE, Runkel N, Hinkelbein W. Low acute toxicity of radiotherapy and radiochemotherapy in patients with cancer of the anal canal and HIV-infection. Acta Oncologica 1997, 36(8):799-802. 10.3109/02841869709001360, 9482685.
52. Edelman S, Johnstone PAS. Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: Outcomes and toxicities. International Journal of Radiation Oncology Biology Physics 2006, 66(1):206-211.
53. Place RJ, Gregorcyk SG, Huber PJ, Simmang CL. Outcome analysis of HIV-positive patients with anal squamous cell carcinoma. Diseases of the Colon & Rectum 2001, 44(4):506-512.
54. Stadler RF, Gregorcyk SG, Euhus DA, Place RJ, Huber PJ, Simmang CL. Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy. Diseases of the Colon & Rectum 2004, 47(8):1305-1309.
55. Brunner TB, Geiger M, Grabenbauer GG, Lang-Welzenbach M, Mantoni TS, Cavallaro A, Sauer R, Hohenberger W, McKenna WG. Phase I trial of the human immunodeficiency virus protease inhibitor Nelfinavir and chemoradiation for locally advanced pancreatic cancer. Journal of Clinical Oncology 2008, 26(16):2699-2706. 10.1200/JCO.2007.15.2355, 18509182.